Drugs / IDE161
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05787587 | Apr 2023 → Oct 2026 expected | breast cancer, colorectal cancer, endometrial cancer, head and neck cancer +4 | IDEAYA Biosciences | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07174583 | Oct 2025 → Jul 2029 expected | small cell lung carcinoma | IDEAYA Biosciences | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IDE161 | “PARG Inhibitor IDE161” NCT05787587 ↗ |
| Action | Inhibit | “PARG Inhibitor IDE161” NCT05787587 ↗ |
| Route | Oral | “oral administration” NCT07174583 ↗ |
| Target | PARG | “PARG Inhibitor IDE161” NCT05787587 ↗ |